Skip to content

The AMD Experts

50196296_795957517416981_458178117475762176_n

Our Team

The MacuLogix team is committed to empowering primary eye care professionals with the technology and tools needed to create AMD Centers of Excellence.

Bill McPhee, the President and CEO of MacuLogix, shares his personal story of why he joined the company and adopted its vision of eliminating blindness caused by AMD.

The AdaptDx is especially useful for optometrists and general ophthalmologists who see many patients with “normal” clinical exams, since it can detect subclinical AMD up to three years before clinical onset. With the AdaptDx, you will be in the front line in detecting these patients and will be able to carefully monitor and treat those with subclinical AMD.

Dr. Shawn Lewis1 Shawn Lewis, MD View all testimonials

Put Our Expertise to Work

Testing with AdaptDx

AdaptDx identifies impaired dark adaptation—the earliest warning sign of AMD.

Guiding AdaptDx Implementation

Each AdaptDx purchase is supported by our AMD Excellence Program™ to help you achieve your patient care and practice revenue goals.

Latest News & Upcoming Events

View More
Press Releases: March 4, 2019

MacuLogix Raises $38.7 Million in Series D Financing Led by Vivo Capital

This funding will be used to further expand the team and company infrastructure to support the growing sales and practice integration efforts of the AdaptDx automated dark adaptometer.

Blog: February 28, 2019

Standing Out in the Crowd

The value we bring to eye care professionals’ practices is what makes us truly stand out in the crowd. By Armond Dantino.

Article: February 15, 2019 | Primary Optometry News

Dark Adaptation; A Biomarker for AMD

Practitioners can use the AdaptDx by Maculogix to test a patient’s dark adaptation, which can be a biomarker for AMD, according to Bill McPhee, CEO of Maculogix.